Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches
Boehringer Ingelheim reported continued strong sales growth in the first half of 2026 (H1 2026),...
China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline
China Resources Pharmaceutical (HKG: 3320) announced today its plan to acquire 188,102,749 shares of Lier...
Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma
Harbour BioMed (HKG: 2142) and Kelun-Biotech (HKG: 6990) announced today that the Investigational New Drug...
Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced today that HRS-8797 Tablets and...
Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR/GLP-1R Agonist for Obesity
Ascletis Pharma Inc. (HKG: 1672) announced today the selection of its fixed-dose combination (FDC) of...
Fosun Pharma Secures NMPA Approval for FXR0906, Liver-Targeted siRNA Therapy for Hypertriglyceridemia
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced today that the Phase...
China Medical System Secures NMPA Approval for CMS-D017, Novel Complement Factor B Inhibitor for AMD
China Medical System Holdings Limited (CMS) (HKG: 0867) announced today that the National Medical Products...
Roche Secures FDA Priority Review for Gazyva in Primary Membranous Nephropathy Based on Phase III MAJESTY Data
Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced today that the US Food and Drug...
Novo Nordisk Secures EU Approval for Wegovy Pill, First Oral Semaglutide 25mg for Obesity Treatment
Novo Nordisk (NYSE: NVO) announced today that the European Commission (EC) has granted marketing authorization...
Lepu Medical Secures NMPA Clinical Trial Approval for MWN110, Novel ActRIIA/B Antibody for Weight Management
Lepu Medical Technology (SHE: 300003) announced on July 15, 2026, that the National Medical Products...
Merck KGaA’s Enpatoran Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus
Merck KGaA (ETR: MRK) announced on July 8, 2026, that the US Food and Drug...
Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset
Braveheart Bio, a Delaware-based biopharmaceutical company founded in 2024, submitted its IPO prospectus to the...
WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028
WuXi Biologics (HKG: 2269) announced on June 16, 2026, a comprehensive Contract Development, Research, and...
China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) issued the...
Johnson & Johnson Reports Q2 2026 Results with 6.6% Sales Growth, Raises Full-Year Guidance
Johnson & Johnson (J&J) (J&J, NYSE: JNJ) announced second-quarter 2026 results, reporting sales growth of...
Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics
Innovent Biologics (HKG: 1801) announced an exclusive license agreement with Spero Therapeutics, Inc. (NASDAQ: SPRO)...
Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger
Hansoh Pharmaceutical (HKG: 3692) announced a dual strategic transaction involving its portfolio company Avere Therapeutics,...
Everest Medicines and JD Healthcare Forge Strategic Digital Healthcare Alliance to Accelerate Innovative Drug Access
Everest Medicines (HKG: 1952) announced a strategic cooperation agreement with JD Healthcare (HKG: 6618) to...
Innovent Biologics Secures Macau Approval for Dual-Immunotherapy Neoadjuvant Regimen in MSI-H/dMMR Colon Cancer
Innovent Biologics (HKG: 1801) announced that its independently developed Daboxin (ipilimumab N01) has received marketing...
Kelun-Biotech’s Sacituzumab Tirumotecan Achieves World’s First ADC-Immunotherapy Phase III Success in PD-L1-Negative NSCLC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that its Phase III clinical study evaluating sacituzumab...